Abstract
The effects of antiestrogens, tamoxifen and ICI 182,780, and aromatase inhibitors, arimidex (anastrozole ZD1033) and letrozole (CGS 20,267), on the growth of tumors were studied in nude mice. In this model, estrogen dependent MCF-7 human breast cancer cells stably transfected with the aromatase gene were inoculated in four sites per mouse. Sufficient estrogen is produced from aromatization of androstenedione supplement (0.1 mg/mouse/day) by the cells to stimulate their proliferation, tumor formation, and maintain the uterus similar to that of the intact mouse. Once the tumors reached a measurable size, the mice were injected with antiestrogen or inhibitor for 35–56 days. Tumor volumes were measured weekly. At autopsy, the tumors were removed, cleaned, and weighed. Statistical data was determined from tumor weights. Both antiestrogens were effective in reducing tumor growth in these mice. Tamoxifen appears to be more effective than ICI 182,780, although the former stimulated the uterine weight whereas the pure antiestrogen did not. However, both aromatase inhibitors were more effective than the antiestrogens. Tumor regression was observed with letrozole. Thus, after-treatment tumor weights were less than those of a group of mice at the start of treatment. The aromatase inhibitors also reduced the weight of the uterus, suggesting that these compounds, as well as the pure antiestrogen, may not cause endometrial proliferation, unlike tamoxifen. These aromatase inhibitors may not only benefit patients who have relapsed from tamoxifen, but may be more effective in patients as first line agents for suppressing the effects of estrogen.
Similar content being viewed by others
References
James VHT, Reed MJ: Steroid hormones and human cancer Prog Res Ther 14: 471–487, 1980
Harris JR, Lippman ME, Veronesi U, Willet W: Medical progress: Breast cancer. New Eng J Med 327: 319–328, 1992
Early Breast Cancer Trials Collaborative Group: Stystemic treatment of early breast cancer by hormonal, cytoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1–15, 1992
Jordan VC: Biochemical pharmacology of antiestrogen action. Pharm Rev 36: 245–276, 1980
Brodie AMH: Aromatase inhibitors in the treatment of breast cancer. J Steroid Biochem Molec Biol 49: 281–287, 1994
Cole MP, Jones CTA, Todd IDH: A new antiestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25: 270–275, 1971
Fornander T, Rutqvist LE, Cedermark B. Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancer. Lancet 1(8630): 117–119, 1989
Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69: 237–238, 1985
Harper MJK, Walpole AL: A new derivative of triphenylethylene: effect on implantation and mode of action in rats. J Reproduction and Fertility 13: 101–119, 1967a
Wakeling AE, Bowler J: Steroidal pure antiestrogen. J Endocr 112: R7–R10, 1987
Wakeling AE, Bowler J: Biology and mode of action of pure antiestrogens. J Steroid Biochem 30: 141–147, 1988
Bowler J, Lilley TJ, Pittman JD, Wakeling AE: Novel steroidal pure antiestrogens. Steroids 54: 71–99, 1989
Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873, 1991
DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE: Investigation of a new pure antiestrogen (ICI182,780) in women with primary breast cancer. Cancer Res 54: 408–414, 1994
Brodie AMH, Schwarzel WC, Shaikh AA, Brodie HJ: The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology 100: 1684–1695, 1977
Goss PE, Powles TJ, Dowsett M, Hutchison G, Brodie AMH, Gazet J-C, Coombes RC: Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report. Cancer Res 46: 4823–4826, 1986
Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AMH: 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Steroids 50: 245–252, 1987
Wiseman LR, McTavish D: Formestane: a review of its pharmacodynamic and pharmacokinetics and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs 45: 66–84
Bajetta E, Zilembo N, Buzzoni R, Noberasco C, Celio L, Bichisao E: Efficacy and tolerability of 4-hydroxyandrostcnedione as first-line treatment in postmenopausal patients with breast cancer after adjuvant therapy. Cancer Treatment Rev 19(Suppl.): 31–36, 1993
Demers LM: Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 30: 95–102, 1994
Plourde PV, Dyroff M, Dukes M: Arimidex: A potent and selective fourth-generation aromatasc inhibitor. Breast Cancer Res Treat 30: 103–111, 1994
Marty M, Gershanovich M, Campos B, Romieu G, Lurie H, Bonaventura T, Jeffery M, Buzzi F, Ludwig H, Bodrigi I, Reichardt P. O'Higgins N, Chaudri HA, Friederich P, Biachoff MA: Letrozole, a new potent, selective aromatase inhibitor (AI) superior to aminoglutethimide (AG) in postmenopausal women with advanced breast cancer (ABC) previously treated with antiestrogens. Proc ASCO 16: 156a, 1997
Buzdar A, Jonat W, Howell A, Yin H, Lee D: Significant improved survival with arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. Proc ASCO 16: 156a, 1997
Yue W, Zhou DJ, Chen S, Brodie AMH: A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54: 5092–5095, 1994
Yue W, Wang J, Savinov A, et al: Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 55: 3073–3077, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lu, Q., Yue, W., Wang, J. et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 50, 63–71 (1998). https://doi.org/10.1023/A:1006004930930
Issue Date:
DOI: https://doi.org/10.1023/A:1006004930930